Effect of high- versus intermediate-purity blood coagulation factor concentrates on HIV-1 replication.
Controversy exists as to whether treatment of HIV-1-seropositive hemophiliacs with blood coagulation products of high purity might help prevent the decline of CD4-positive lymphocytes and thus delay progression toward AIDS. As viral load has recently been shown to be associated with disease progression in HIV-1 infection, we tested for a possible direct interference of high- or intermediate-purity blood coagulation products with replication of HIV-1. The data obtained revealed comparable replication of HIV-1 in the presence and absence of all blood coagulation products tested (assessed by PCR-based quantitation of proviral HIV-1 DNA in infected cells after a 10-day incubation period). These data suggest that coagulation factor concentrates per se will also have no direct effect on HIV-1 replication in vivo.
Schögl
D
D
Institute of Immunology, University of Vienna, Austria.
Zimmermann
K
K
Turecek
P L
PL
Schwarz
H P
HP
Eibl
M M
MM
Mannhalter
J W
JW
D018791:CD4 Lymphocyte Count / Q000187:drug effects; D004279:DNA, Viral / Q000032:analysis; D018450:Disease Progression; D005169:Factor VIII / Q000302:isolation & purification* / Q000494:pharmacology*; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011533:Proviruses / Q000235:genetics / Q000302:isolation & purification; D014779:Virus Replication / Q000187:drug effects*
D004279:DNA, Viral; D005169:Factor VIII